Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting

• Main Authors: Bobbie J. Rimel (Author), Dana M. Chase (Author), Jessica Perhanidis (Author), Armen A. Ghazarian (Author), Ella Xiaoyan Du (Author), Travis Wang (Author), Jinlin Song (Author), Amanda K. Golembesky (Author), Jean A. Hurteau (Author), Linda Kalilani (Author), Ritu Salani (Author), Bradley J. Monk (Author)
• Format: Book
• Published: Elsevier, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi) are metabolized either via carboxylesterase (niraparib) or cytochrome P450 (CYP) enzymes (olaparib and rucaparib). Patients with advanced epithelial ovarian cancer (aOC) who receive concomitant medication metabolized by the CYP s...